The Complex Products do not constitute a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA). Therefore, the Complex Products are not subject to authorisation or supervision by the Swiss Financial Market Supervisory Authority (FINMA). Investors bear the issuer risk. The Complex Products are structured products within the meaning of the CISA. This simplified prospectus is only available in English.

I. Product Description

The Complex Products allow the holders to benefit from several payments of the Interest Amount and Premium Amount, irrespective of the development of the value of the Underlyings. Therefore, the potential return on a Complex Product is limited to the positive difference between (i) the aggregate of Interest Amounts and Premium Amounts scheduled to be paid thereunder, plus the Final Redemption Amount, and (ii) the Issue Price (or, if different, the price the relevant investor paid for such Complex Product) (i.e., the return is capped). As long as none of the Barriers have been reached or breached during the Barrier Observation Period, the Final Redemption Amount is equal to 100% of the Denomination.

If the value of the Underlyings decreases, the Final Redemption Amount may be substantially lower than the Issue Price. If a Barrier has been reached or breached during the Barrier Observation Period and the Final Level of at least one Underlying is below its Strike on the Final Fixing Date, the potential loss associated with an investment in Complex Products is linked to the negative performance of the Worst-Performing Underlying. Therefore, a total or substantial loss of the amount invested in Complex Products is possible, although any such loss is limited to the amount invested.

### Underlyings

<table>
<thead>
<tr>
<th>Underlyings</th>
<th>Bloomberg Ticker</th>
<th>Exchange</th>
<th>Strike (100%)</th>
<th>Barrier (69%)</th>
<th>Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nestlé S.A.</td>
<td>NESN SE EQUITY</td>
<td>SIX Swiss Exchange</td>
<td>CHF 91.11</td>
<td>CHF 62.8659</td>
<td>10.9757</td>
</tr>
<tr>
<td>Roche Holding AG Non-voting equity security</td>
<td>ROG SE EQUITY</td>
<td>SIX Swiss Exchange</td>
<td>CHF 277.72</td>
<td>CHF 191.6268</td>
<td>3.6007</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>NOVN SE EQUITY</td>
<td>SIX Swiss Exchange</td>
<td>CHF 89.11</td>
<td>CHF 61.4859</td>
<td>11.2221</td>
</tr>
</tbody>
</table>

### Indicative Issue Details

<table>
<thead>
<tr>
<th>Security Codes</th>
<th>Swiss Sec. No.:</th>
<th>ISIN:</th>
<th>RIC:</th>
<th>SIX Symbol:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>45 833 047</td>
<td>CH 045 833 047 6</td>
<td>CH45833047=CSZH</td>
<td>AECZCS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issuer</th>
<th>Credit Suisse AG, Zurich, acting through its London Branch, London (Moody’s: A1 / S&amp;P: A)</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Issuer</td>
<td>is authorized and supervised by FINMA in Switzerland and by the Prudential Regulation Authority and the Financial Conduct Authority in the United Kingdom.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lead Manager</th>
<th>Credit Suisse AG, Zurich</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paying Agent</td>
<td>Credit Suisse AG, Zurich</td>
</tr>
<tr>
<td>Calculation Agent</td>
<td>Credit Suisse International, London</td>
</tr>
<tr>
<td>Issue Size</td>
<td>up to CHF 10'000'000 (may be increased/decreased at any time)</td>
</tr>
<tr>
<td>Denomination</td>
<td>CHF 1'000</td>
</tr>
<tr>
<td>Minimum Investment</td>
<td>CHF 1'000</td>
</tr>
<tr>
<td>Issue Price</td>
<td>100%</td>
</tr>
<tr>
<td>Subscription Period</td>
<td>until 12 March 2019, 15:00 CET</td>
</tr>
<tr>
<td>Initial Fixing Date</td>
<td>12 March 2019, being the date on which the Strike and the Barrier and the Ratio is fixed, and from which date the Complex Products may be traded.</td>
</tr>
<tr>
<td>Issue/Payment Date</td>
<td>19 March 2019, being the date on which the Complex Products are issued and the Issue Price is paid.</td>
</tr>
<tr>
<td>Last Trading Date</td>
<td>12 March 2021, until the official close of trading on SIX Swiss Exchange Ltd, being the last date on which the Complex Products may be traded.</td>
</tr>
<tr>
<td>Final Fixing Date</td>
<td>12 March 2021, being the date on which the Final Level will be fixed.</td>
</tr>
<tr>
<td>Final Redemption Date</td>
<td>19 March 2021, being the date on which each Complex Product will be redeemed at the Final Redemption Amount, unless previously redeemed, repurchased or cancelled.</td>
</tr>
<tr>
<td>Listing</td>
<td>SIX Swiss Exchange Ltd</td>
</tr>
<tr>
<td>Trading/Secondary Market</td>
<td>Under normal market conditions, the Issuer, acting through one of its affiliates, will endeavour to provide a secondary market, but is under no legal obligation to do so. Upon investor demand, the Issuer, acting through one of its affiliates, will endeavour to provide bid/offer prices for the Complex Products, depending on actual market conditions. There will be a price difference.</td>
</tr>
</tbody>
</table>

(1) Herein called the “Complex Products”.

(2) Investing in the Complex Products requires specific knowledge on the part of the potential investor regarding the Complex Products and the risks associated therewith. It is recommended that the potential investor obtains adequate information regarding the risks associated with the Complex Products before making an investment decision.

(3) See Swiss Derivatives Map at www.ssap-association.ch.
between bid and offer prices (spread). The Complex Products are traded in percentage of the Denomination at a clean price, i.e., the trading price does not contain accrued interest or premium, which is calculated separately, and are booked accordingly. Indicative trading prices may be obtained on Reuters and Bloomberg.

**Minimum Trading Lot / Subscription Amount**  
CHF 1'000

**Clearing**  
SIX SIS Ltd, Euroclear S.A., Clearstream Banking

**Form**  
Uncertificated Securities

**Governing Law/Jurisdiction**  
Swiss Law/Courts of Zurich 1

**Publication**  
Any amendment to the Complex Products will be published on www.credit-suisse.com/derivatives.

**Main Sales and Offering Restrictions**  
U.S.A., U.S. Persons, Singapore, European Economic Area, Hong Kong, United Kingdom, Kingdom of Bahrain

Further information as well as a non-exhaustive list of additional sales and offering restrictions are available in the Base Prospectus for the issuance of Yield Enhancement Products of Credit Suisse AG dated 21 June 2018 on www.credit-suisse.com/derivatives under “Base Prospectuses”.

**General:** Except as set out in the documentation, no action has been or will be taken that would permit a public offering of Complex Products or possession or distribution of any offering material in relation to Complex Products in any jurisdiction where action for that purpose is required. No offers, sales, deliveries or transfers of Complex Products or the Underlyings (if any) to be delivered upon redemption of the Complex Products, or distribution of any offering material relating to Complex Products, may be made in or from any jurisdiction except in circumstances which will result in compliance with any applicable laws and regulations and will not impose any obligations on the Issuer or the relevant dealer(s).

### Indicative Interest | Premium

<table>
<thead>
<tr>
<th>Interest Amount</th>
<th>0.00% p.a. of the Denomination.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Premium Amount</td>
<td>5.25% p.a. of the Denomination.</td>
</tr>
<tr>
<td>Interest/Premium Payment Date(s)</td>
<td>19 June 2019, 19 September 2019, 19 December 2019, 19 March 2020, 19 June 2020, 21 September 2020, 21 December 2020 and 19 March 2021, being the date(s) on which the Issuer shall pay the Interest Amount and the Premium Amount per Complex Product to the holders, unless previously redeemed, repurchased or cancelled.</td>
</tr>
<tr>
<td>Business Day Convention/ Day Count Fraction</td>
<td>Modified following, unadjusted, 30/360.</td>
</tr>
</tbody>
</table>

### Indicative Early Redemption

- **Issuer Call Option**  
  The Issuer may redeem the Complex Products early in whole, but not in part, on any Optional Early Redemption Date at the Optional Early Redemption Price, provided that the Issuer has exercised such right on or prior to the relevant Call Option Exercise Date.

- **Call Option Exercise Date(s)**  
  12 March 2020, 12 June 2020, 14 September 2020 or 14 December 2020

- **Optional Early Redemption Date(s)**  
  19 March 2020, 19 June 2020, 21 September 2020 or 21 December 2020

- **Optional Early Redemption Price**  
  100% of the Denomination

### Indicative Final Redemption

- **Final Redemption Amount**  
  (i) If no Barrier Event has occurred, a cash amount equal to 100% of the Denomination; or
  (ii) If a Barrier Event has occurred, and
     (a) the Final Level of each Underlying is at or above its Strike, a cash amount equal to 100% of the Denomination; or
     (b) the Final Level of at least one Underlying is below its Strike, the number of Worst-Performing Underlyings specified in the Ratio of the Worst-Performing Underlying. Fractions will not be cumulated and will be paid in cash (based on the Final Level of the Worst-Performing Underlying). In this case, the investor will have to bear the usual transaction fees, based on the Strike of the Worst-Performing Underlying.

- **Settlement Type**  
  physical settlement or cash settlement.

- **Ratio**  
  with respect to each Underlying, the number of Underlying(s) per Complex Product based on the Strike of such Underlying.

- **Worst-Performing Underlying**  
  out of all the Underlyings, the Underlying in respect of which its Final Level divided by its Strike results in the lowest value.

- **Strike**  
  with respect to each Underlying, 100% of its level at the Valuation Time on the Initial Fixing Date.

- **Final Level**  
  with respect to each Underlying, 100% of its level at the Valuation Time on the Final Fixing Date.

- **Valuation Time**  
  with respect to each Underlying, its scheduled closing time.

- **Barrier**  
  with respect to each Underlying, 69% of its Strike.

- **Barrier Event**  
  if the level of any Underlying at any time (observed continuously) on any Barrier Observation Date is at or below its Barrier.

- **Barrier Observation Dates**  
  each exchange business day during the Barrier Observation Period.

- **Barrier Observation Period**  
  from and excluding the Initial Fixing Date to and including the Final Fixing Date.

### Indicative Distribution Fee

- **Distribution Fee**  
  up to 0.65% p.a. (in percent of the Denomination and included in the Issue Price)

### Swiss Taxation (Indicative)

The following statements and discussions of certain Swiss tax considerations relevant to the purchase, ownership and disposition of the Complex Products are of a general nature only and do not address all potential tax consequences of an investment in the Complex Product under Swiss law. This summary is based on treaties, laws, regulations, rulings and decisions currently in effect, all of which are subject to change. It does not address the tax consequences of the Complex Products in any jurisdiction other than Switzerland.

Tax treatment depends on the individual tax situation of each investor and may be subject to change.
Potential investors will, therefore, need to consult their own tax advisors to determine the special tax consequences of the purchase, ownership and sale or other disposition of a Complex Product. In particular, the precise tax treatment of a holder of a Complex Product needs to be determined with reference to the applicable law and practice at the relevant time.

The issuers shall be liable for all current and future taxes and duties as a consequence of an investment in Complex Products. The income tax treatment as depicted below is applicable to individual persons with tax residence in Switzerland and private assets. Withholding tax and stamp taxes are applicable to all investors; however, specific rules apply with respect to certain types of investors and transactions.

No Swiss withholding tax (Vereinnahmungssteuer).

Secondary market transactions are subject to securities transfer stamp tax (0.15%) for Swiss resident investors. [TK-Code 22]

The delivery of the Worst-Performing Underlying, if any, is subject to securities transfer stamp tax at a rate of up to 0.15%. In case of Underlying(s) issued by a Swiss issuer and of up to 0.30%. In case of Underlying(s) issued by a non-Swiss issuer, provided, in both cases, that a Swiss securities dealer for purposes of securities transfer stamp tax, such as a Swiss bank, is involved as a party or an intermediary in the transaction and no exemption applies. The securities transfer stamp tax is based on the Strike of the Worst-Performing Underlying.

The interest payment of 0.00% p.a. is subject to income tax for Swiss resident private investors. The premium payment of 5.25% p.a. qualifies for tax-free capital gain for Swiss resident private investors.

Withholding Tax

Investors in this Complex Product should note that payments under this Complex Product may be subject to withholding taxes (including, but not limited to, United States withholding taxes imposed pursuant to FATCA (as defined in the Base Prospectus) or Section 871(m) of the US Internal Revenue Code of 1986, as amended). Any payments due under this Complex Product shall be paid net of such tax. Please refer to the Terms and Conditions and the Base Prospectus for further detail. In the event that any withholding taxes are applicable to any amount payable under this Complex Product, the Issuer shall not be obligated to pay additional amounts in connection with any amounts so withheld.

The Issuer expressly disclaims all liability in respect of any tax implications.

II. Profit and Loss Prospects

Profit Prospects

The Complex Products allow the holders to benefit from several payments of the Interest Amount and Premium Amount, irrespective of the development of the value of the Underlyings. Therefore, the potential return on a Complex Product is limited to the positive difference between (i) the aggregate of Interest Amounts and Premium Amounts scheduled to be paid thereunder, plus the Final Redemption Amount, and (ii) the Issue Price (or, if different, the price the relevant investor paid for such Complex Product) (i.e., the return is capped). As long as none of the Barriers have been reached or breached during the Barrier Observation Period, the Final Redemption Amount is equal to 100% of the Denomination.

Loss Prospects

If the value of the Underlyings decreases, the Final Redemption Amount may be substantially lower than the Issue Price. If a Barrier has been reached or breached during the Barrier Observation Period and the Final Level of at least one Underlying is below its Strike on the Final Fixing Date, the potential loss associated with an investment in Complex Products is linked to the negative performance of the Worst-Performing Underlying. Therefore, a total or substantial loss of the amount invested in Complex Products is possible, although any such loss is limited to the amount invested.

Calculation Examples of the Final Redemption Amount (unless an Early Redemption occurs)

<table>
<thead>
<tr>
<th>Any Barrier reached or breached during the Barrier Observation Period?</th>
<th>Performance of the Worst-Performing Underlying on the Final Fixing Date:</th>
<th>Final Redemption Amount per Complex Product:</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>Not relevant</td>
<td>CHF 1’000 (none of the Barriers have been reached or breached during the Barrier Observation Period).</td>
</tr>
<tr>
<td>Yes</td>
<td>+ 5%</td>
<td>CHF 1’000 (the Final Level of the Worst-Performing Underlying is at or above its Strike).</td>
</tr>
<tr>
<td>Yes</td>
<td>- 70%</td>
<td>Delivery of the number of Underlying(s) stated in the Ratio of the Worst-Performing Underlying.</td>
</tr>
</tbody>
</table>

This table shows exemplary redemption scenarios regarding the Final Redemption Amount as per the Final Redemption Date for illustrative purposes only and does not constitute a price indication for the Complex Products or the Underlyings. During the term of the Complex Products, additional risks and other factors may influence the market value of the Complex Products. As a consequence, the pricing in the secondary market may differ significantly from the above table.

III. Important Risks for Investors

Important Risks

Issuer Risk

Investors bear the Issuer risk. The Complex Products’ retention of value is dependent not only on the development of the value of the Underlying(s), but also on the creditworthiness of Credit Suisse AG, which may change over the term of the Complex Products. Furthermore, the Issuer’s ability to fulfill its obligations under the Complex Products may be affected by certain other factors, including liquidity risks, market risks, credit risks, cross-border and foreign exchange risks, operational risks, legal and regulatory risks and competition risks. The Complex Products are direct, unconditional, unsecured and unsubordinated obligations of Credit Suisse AG and are not covered by any compensation or insurance scheme (such as a bank deposit protection scheme). If Credit Suisse AG were to become insolvent, claims of investors in Complex Products would rank equally in right of payment with all other unsecured and unsubordinated obligations of Credit Suisse AG, except such obligations given priority by law. In such a case, investors in Complex Products may suffer a loss of all or a portion of their investment therein, irrespective of any favourable development of the other value determining factors, such as the performance of the Underlying(s).

Credit Suisse AG is licensed as a bank pursuant to the Swiss Federal Act on Banks and Saving Banks and as a security dealer pursuant to the Swiss Federal Act on Stock Exchanges and Securities Trading and is subject to supervision by the FINMA. Credit Suisse AG London Branch is authorised and regulated by FINMA in Switzerland, authorised by the Prudential Regulation Authority, is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from the Issuer on request.

Product Risk

Complex Products involve substantial risks and potential investors must have the knowledge and experience necessary to enable them to evaluate the risks and merits of an investment in Complex Products.
Prospective investors should:

- ensure that they understand the nature of the risks posed by, and the extent of their exposure under, the Complex Products;
- make all pertinent inquiries they deem necessary without relying on the Issuer or any of its affiliates or officers or employees;
- consider the suitability of the Complex Products as an investment in light of their own circumstances, investment objectives, tax position and financial condition;
- consider carefully all the information set forth in the legally binding Terms and Conditions as well as all other sections of the Prospectus (including any documents incorporated by reference therein);
- consult their own legal, tax, accounting, financial and other professional advisors to assist them determining the suitability of Complex Products for them as an investment.

Risk of Total Loss

Complex Products involve a high degree of risk, and prospective investors in Complex Products should recognise that Complex Products may under certain circumstances have a redemption value of zero and the payment(s) of Interest Amount and Premium Amount scheduled to be made thereunder may not be made. Prospective investors in Complex Products should therefore be prepared to sustain a partial or total loss of the amount of their investment therein.

Complex Products are unsecured obligations

Complex Products are direct, unconditional, unsecured and unsubordinated obligations of Credit Suisse AG and are not covered by any compensation or insurance scheme (such as a bank deposit protection scheme). If Credit Suisse AG were to become insolvent, claims of investors in Complex Products would rank equally in right of payment with all other unsecured and unsubordinated obligations of Credit Suisse AG, except such obligations given priority by law. In such a case, investors in Complex Products may suffer a loss of all or a portion of their investment therein, irrespective of any favourable development of the other value determining factors, such as the performance of the Underlyings.

Capped Profit Potential

Investors in Complex Products should be aware that the profit potential in relation thereto is capped. Therefore, a direct investment in the Underlyings may lead to a greater return than an investment in the Complex Products.

Unpredictable Market Value of the Complex Products

The market value of, and expected return on, Complex Products may be influenced by a number of factors, some or all of which may be unpredictable (and which may offset or magnify each other), such as (i) supply and demand for Complex Products, (ii) the value and volatility of the Underlyings, (iii) economic, financial, political and regulatory or judicial events that affect Credit Suisse AG, the Underlyings or financial markets generally, (iv) interest and yield rates in the market generally, (v) the time remaining until the Final Redemption Date, (vi) the difference between the level of any Underlying and the relevant threshold, (vii) Credit Suisse AG’s creditworthiness and (viii) dividend payments on the Underlyings, if any.

Trading Market for Complex Products

The trading market for Complex Products may be limited, or may never develop at all, which may adversely impact the market value of such Complex Products or the ability of a holder thereof to sell such Complex Products.

Exposure to the Performance of the Underlyings

Complex Products represent an investment linked to the performance of the Underlyings and potential investors should note that any amount payable, or other benefit to be received, under Complex Products will depend upon the performance of the Underlyings. Potential investors in Complex Products should be familiar with the behaviour of the Underlyings and thoroughly understand how the performance of the Underlyings may affect payments (or any other benefit to be received) under, or the market value of, Complex Products. The past performance of the Underlyings is not indicative of future performance. The market value of a Complex Product may be adversely affected by postponement or alternative provisions for the valuation of the level of any Underlying.

Exchange Rate Risks

The settlement currency may not be the currency of the home jurisdiction of the investor in the Complex Products. Therefore, fluctuations in exchange rates may adversely affect the market value of a Complex Product or the value of the Underlyings.

Broad Discretionary Authority of the Calculation Agent

The Calculation Agent has broad discretionary authority to make various determinations and adjustments under Complex Products, any of which may have an adverse effect on the market value thereof or amounts payable or other benefits to be received thereunder. Any such discretion exercised by, or any calculation made by, the Calculation Agent (in the absence of manifest error) shall be binding on the Issuer and all holders of the Complex Products.

Further Product Specific Risks

Investors in the Complex Products should be aware that an investment therein may result in a loss upon redemption if a Barrier Event has occurred and the Final Level of at least one Underlying is below its Strike. Consequently, the potential loss associated with an investment in the Complex Products is linked to the negative performance of the Worst-Performing Underlying, which is the Underlying with the worst performance out of all Underlyings, and investors therein should be prepared to sustain a partial or total loss of their investment.

Furthermore, investors in the Complex Products should be aware that the timing of redemption of the Complex Products is uncertain since the Issuer is entitled to redeem the Complex Products in whole but not in part prior to the Final Redemption Date. The Issuer is likely to early redeem such Complex Products when its cost of borrowing is lower than the yield on such Complex Products. As a result, (i) if the Issuer exercises its right to early redeem the Complex Products, investors in such Complex Products will not be able to participate in any performance of the Underlying(s) after the date of such early redemption and (ii) investors in such Complex Products may incur additional transaction costs as a consequence of reinvesting proceeds received upon any early redemption and the conditions for such a reinvestment may be less favourable than the relevant investor’s initial investment in the Complex Products. If the Issuer exercises its call option, investors should note that no Interest Amounts or Premium Amounts that would otherwise have been due after the date of such early redemption will be paid.

This risk disclosure notice cannot disclose all the risks. Therefore, potential investors in Complex Products should consult the latest version of the ‘Special Risks in Securities Trading’ risk disclosure brochure (the ‘Risk Disclosure Brochure’) and the Prospectus of which the Terms and Conditions of the Complex Products form a part.
The latest version of the Risk Disclosure Brochure can be obtained, free of charge, from the head office of Credit Suisse AG in Zurich, by calling +41 44 333 2144 or via facsimile no: +41 44 333 8403, or accessed via Internet at the Swiss Bankers Association’s website: www.swissbanking.org (under the following path: www.swissbanking.org/en/services/library/studies-reports).

Important Notices

By investing in the Complex Products, an investor acknowledges having read and understood the following terms:

Any information regarding the Underlying(s) contained in this document consists only of a summary of certain publicly available information. Any such information does not purport to be a complete summary of all material information about such Underlying(s) contained in the relevant publicly available information. The Issuer only accepts responsibility for accurately reproducing such information contained in publicly available information. Otherwise neither the Issuer nor any of its affiliates accept further or other responsibility or make any representation or warranty (express or implied) in respect of such information.

The Issuer is acting solely as an arm’s length contractual counterparty and neither the Issuer nor any affiliate is acting as the financial advisor or fiduciary of any potential investor in the Complex Products unless it has agreed to do so in writing.

The information and views contained herein are those of the Issuer and/or are derived from sources believed to be reliable. This document is not the result of a financial analysis and, therefore, is not subject to the ‘Directives on the Independence of Financial Research’ issued by the Swiss Bankers Association. The contents of this document therefore do not fulfil the legal requirements for the independence of financial analyses and there is no restriction on trading prior to publication of financial research.

In connection with this Complex Product, the Issuer and/or its affiliates may pay to third parties, including affiliates, remunerations (distribution fee) that may be factored into the terms of this Complex Product. The Issuer and/or its affiliates may also offer such remunerations to third parties in the form of a discount on the price of the product. Receipt or potential receipt of such remunerations may lead to a conflict of interests. Internal revenue allocation may lead to a similar effect. Further information can be found under "Product Description". Finally, third parties or the investor’s bank may impose a commission/brokerage fee in connection with the purchase/sale of or subscription to the Complex Product. Investors in the Complex Product may request further information from their bank/relationship manager.

Where not explicitly otherwise stated, the Issuer has no duty to invest in the Underlying(s) and an investor in Complex Products has no recourse to the Underlying(s) or to any return thereon. The issue price of the Complex Products will reflect the customary fees and costs charged on the level of the Underlying(s). Certain built-in costs are likely to adversely affect the value of the Complex Products.

The Complex Products are complex structured financial instruments and involve a high degree of risk. They are intended only for investors who understand and are capable of assuming all risks involved. Before entering into any transaction involving the Complex Products, a potential investor should determine if the Complex Products suit his or her particular circumstance and should independently assess (with his or her professional advisors) the specific risks (maximum loss, currency risks, etc.) and the legal, regulatory, credit, tax and accounting consequences. The Issuer makes no representation as to the suitability or appropriateness of the Complex Products for any particular potential investor or as to the future performance of the Complex Products. This document does not replace a personal conversation between a potential investor and his or her relationship manager and/or professional advisor (e.g. legal, tax or accounting advisor), which is recommended by the Issuer before any investment decision. Therefore, any potential investor in Complex Products is requested to ask his or her relationship manager to provide him or her with any available additional information regarding Complex Products.

Historical data on the performance of the Complex Products or the Underlying(s) is no indication of future performance. No representation or warranty is made that any indicative performance or return indicated will be achieved in the future. Neither this document nor any copy thereof may be sent, taken into or distributed in the United States or to any U.S. person or in any other jurisdiction except under circumstances that will result in compliance with the applicable laws thereof.

Credit Suisse AG or one of its affiliates may provide a secondary market for non-listed Complex Products through its organized trading system. The rulebook of the organized trading system and further information can be found at credit-suisse.com/ohs. By submitting an order in the Complex Product, the investor confirms that secondary market orders may be executed on the organized trading system and that he/she consents to adhere to the rulebook.

Additional Important Information for UK Clients

To the extent communicated in the United Kingdom ("UK") or capable of having an effect in the UK, this document constitutes a financial promotion which has been approved by Credit Suisse (UK) Limited. Credit Suisse (UK) Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority for the conduct of investment business in the UK. The registered address of Credit Suisse (UK) Limited is Five Cabot Square, London, E14 4QR. You should be aware that the protection provided to retail clients by the UK Financial Services and Markets Act 2000 do not apply if this product is provided to you by a non-UK regulated entity within the Credit Suisse Group, including Credit Suisse AG, Zurich. In particular, you will not be entitled to compensation from the UK Financial Services Compensation Scheme nor will you be entitled to the benefits provided by the UK Financial Ombudsman Service.

This document constitutes the Simplified Prospectus for the Complex Products in accordance with Article 5 CISA. The prospectus requirements of Article 652a/Article 1156 of the Swiss Code of Obligations are not applicable. The Simplified Prospectus is of summary nature with a view to include the information required by Article 5 CISA and the Guidelines of the Swiss Bankers Association. The legally binding terms and conditions for the Complex Products are set forth in the final terms (the Final Terms) within the meaning of the Additional Rules for the Listing of Derivatives of the SIX Swiss Exchange Ltd and, together with the Base Prospectus for the issuance of Yield Enhancement Products of Credit Suisse AG dated 21 June 2018 (as supplemented as of the date of the Final Terms, the Base Prospectus), constitutes the listing prospectus (the Listing Prospectus) for the Complex Products. Copies of the Listing Prospectus and the documents incorporated by reference therein may be obtained free of charge from Credit Suisse AG, Transaction Advisory Group, VUC 23, P.O. Box, 8070 Zurich, Switzerland. This document does not constitute an offer or an invitation to enter into any type of financial transaction.

This document may not be reproduced either in whole or in part without the prior written approval of the Issuer.